Conjugated estrogens combined with bazedoxifene: the first approved tissue selective estrogen complex therapy (Q38192058)

30 August 2017

1 reference

title

Conjugated estrogens combined with bazedoxifene: the first approved tissue selective estrogen complex therapy (English)

1 reference

30 August 2017

1 reference

Maryam Sharifi

1

1 reference

30 August 2017

E Michael Lewiecki

series ordinal

2

1 reference

30 August 2017

language of work or name

English

0 references

publication date

3 March 2014

1 reference

Expert Review of Clinical Pharmacology

30 August 2017

published in

1 reference

30 August 2017

volume

7

1 reference

30 August 2017

issue

3

1 reference

30 August 2017

page(s)

281-291

1 reference

Symptoms of menopause: hot flushes

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

Is there a menopausal syndrome? Menopausal status and symptoms across racial/ethnic groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

Bazedoxifene + conjugated estrogens in HT for the prevention of osteoporosis and treatment of vasomotor symptoms associated with the menopause

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

MRI-measured bone marrow adipose tissue is inversely related to DXA-measured bone mineral in Caucasian women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

Re: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

Bazedoxifene and bazedoxifene combined with conjugated estrogens for the management of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

The 2012 hormone therapy position statement of: The North American Menopause Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

Tissue-selective estrogen complexes: a promising option for the comprehensive management of menopausal symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

Tissue selective estrogen complex combinations with bazedoxifene/conjugated estrogens as a model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

Tissue selective estrogen complexes (TSECs) differentially modulate markers of proliferation and differentiation in endometrial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

Global profiling of TSEC proliferative potential by the use of a reporter mouse for proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

Tissue-selective estrogen complexes for postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

Endometrial profile of bazedoxifene acetate alone and in combination with conjugated equine estrogens in a primate model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

Inhibitory effects of a bazedoxifene/conjugated equine estrogen combination on human breast cancer cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

Research resource: Transcriptional profiling in a cellular model of breast cancer reveals functional and mechanistic differences between clinically relevant SERM and between SERM/estrogen complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

Effects of the conjugated equine estrogen/bazedoxifene tissue-selective estrogen complex (TSEC) on mammary gland and breast cancer in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor α and cyclin D1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

Skeletal effects of bazedoxifene paired with conjugated estrogens in ovariectomized rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

Transition from estrogen therapy to raloxifene in postmenopausal women: effects on treatment satisfaction and the endometrium-a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

Recent insights into the varying activity of estrogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

Hot flush symptom-free days with bazedoxifene/conjugated estrogens in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

Further psychometric property development of the Menopause-Specific Quality of Life questionnaire and development of a modified version, MENQOL-Intervention questionnaire.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

Breast effects of bazedoxifene-conjugated estrogens: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

The tissue selective estrogen complex: a novel approach to the treatment of menopausal symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

Profile of bazedoxifene/conjugated estrogens for the treatment of estrogen deficiency symptoms and osteoporosis in women at risk of fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

Pharmacokinetic evaluation of bazedoxifene for the treatment of osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

Using bazedoxifene plus conjugated estrogens for treating postmenopausal women: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.893819

10.1586/17512433.2014.893819

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference